Table 1 Cell viabilities of GBM cells and non-cancerous cells after treatments with PENAO, DCA and combination
From: Dual-targeting of aberrant glucose metabolism in glioblastoma
Compounds | IC 50 values | ||||||
|---|---|---|---|---|---|---|---|
GBM cell lines | Non-canerous cell lines | ||||||
U87 | U251 | DBTRG | LN229 | BAH1 | MRC-5 | Normal human astrocytes | |
PENAO ( μM) | 3.5 ± 0.5 | 2.5 ± 0.4 | 3.5 ± 0.2 | 3.0 ± 0.4 | 3.4 ± 0.3 | 8.7 ± 0.7 | 7.9 ± 1.2 |
DCA (mM) | 25.6 ± 6.2 | 24.3 ± 5.7 | 28.2 ± 4.5 | 40.3 ± 5.2 | 46.5 ± 6.2 | n.d. | n.d. |